Jindu Shengke has completed a nearly hundred million yuan Series A financing.

On June 12th, Shenzhen Jindu Biomedical Technology Co., Ltd. announced the completion of its Series A financing round. The round was led by Gaotexia Investment, and nearly one hundred million yuan will be mainly used for deepening the research and development of the physical AI underlying architecture, iterating and upgrading the BioFord Agent autonomous scientific research platform, and expanding its global market layout.